Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Association Between Cyp3a5 Genetic Polymorphisms With Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients Pubmed



Ghafari S1 ; Dashtikhavidaki S1 ; Khatami MR2 ; Ghahremani MH1 ; Seyednejad SA3 ; Behpajooh A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Kidney Diseases Published:2019


Abstract

Introduction. Tacrolimus is the cornerstone of immunosuppressive therapy in organ transplantation with variable inter-individual pharmacokinetics. This study assessed the relationship between CYP3A5/3A4 polymorphisms and tacrolimus dose requirement as well as 6-month transplant outcomes in Iranian kidney transplant recipients. Methods. In this prospective study, 110 adult kidney transplant recipients treated with tacrolimus were genotyped for the presence of common SNPs: rs776746: A > G (CYP3A5*3). Patients who carried at least one CYP3A5*1 allele were known as CYP3A5 expressers while those who were CYP3A5*3/*3 homozygotes were classified as CYP3A5 non-expressers. Results. The daily tacrolimus dose was significantly higher and tacrolimus dose adjusted trough levels (C/D ratio) was significantly lower in CYP3A5 expressers compared with non-expressers (P <.05). Although the incidence of clinically suggested acute allograft rejection was significantly higher (OR = 0.365 [95% CI: 0.14 - 0.93]; P <.05) and median time to first acute rejection was sooner among CYP3A5 expressers compared with non-expressers (12.17 vs. 26.83 days, P <.05); however, estimated glomerular filtration rate, incidence of biopsy proven acute rejection and delayed graft function and 6-month patients’ and grafts’ survival did not differ between the two groups. Conclusion. CYP3A5 genetic polymorphism is significantly associated with required tacrolimus dose. After achieving desired tacrolimus blood level, although some transplant outcomes such as the incidence of clinically suggested acute rejection and time to first rejection were different between CYP3A5 expressers and non-expressers, however, other clinical outcomes did not differ between groups. Therefore, it is not the time to routinely assess kidney transplant recipients for CYP3A5 genetic polymorphism before transplantation. © 2019, Iranian Society of Nephrology. All rights reserved.